Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Assets (2018 - 2025)

Historic Assets for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to $282.3 million.

  • Arcturus Therapeutics Holdings' Assets fell 2382.57% to $282.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $282.3 million, marking a year-over-year decrease of 2382.57%. This contributed to the annual value of $344.1 million for FY2024, which is 1987.25% down from last year.
  • Per Arcturus Therapeutics Holdings' latest filing, its Assets stood at $282.3 million for Q3 2025, which was down 2382.57% from $309.3 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Assets ranged from a high of $481.5 million in Q1 2021 and a low of $282.3 million during Q3 2025
  • Moreover, its 5-year median value for Assets was $392.8 million (2021), whereas its average is $390.3 million.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' Assets skyrocketed by 56774.1% in 2021, and later crashed by 3242.75% in 2022.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Assets (Quarter) stood at $392.8 million in 2021, then grew by 14.66% to $450.4 million in 2022, then decreased by 4.66% to $429.4 million in 2023, then fell by 19.87% to $344.1 million in 2024, then decreased by 17.94% to $282.3 million in 2025.
  • Its last three reported values are $282.3 million in Q3 2025, $309.3 million for Q2 2025, and $331.8 million during Q1 2025.